Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment

• Published in: Journal of rheumatology Vol. 46; no. 1; p. 7
• Main Authors: Smolen, Josef S, Genovese, Mark C, Takeuchi, Tsutomu, Hyslop, David L, Macias, William L, Rooney, Terence, Chen, Lei, Dickson, Christina L, Riddle Camp, Jennifer, Cardillo, Tracy E, Ishii, Taeko, Winthrop, Kevin L
• Format: Journal Article
• Language: English
• Published: Canada 01.01.2019
• Subjects: RHEUMATOID ARTHRITIS; BARICITINIB; CLINICAL TRIALS; SAFETY; JANUS KINASE INHIBITOR

Baricitinib is an oral, once-daily selective Janus kinase (JAK1/JAK2) inhibitor for adults with moderately to severely active rheumatoid arthritis (RA). We evaluated baricitinib's safety profile through 288 weeks (up to September 1, 2016) with an integrated database [8 phase III/II/Ib trials, 1...